Research for AstraZeneca Pharma India receives CDSCO approval for Trastuzumab Deruxtecan for adults with HER2-positive early breast cancer and residual invasive disease after neoadjuvant treatment - aVenture Research
astrazeneca.in
AstraZeneca Pharma India receives CDSCO approval for Trastuzumab Deruxtecan for adults with HER2-positive early breast cancer and residual invasive disease after neoadjuvant treatment
Bangalore, 8th August 2026: AstraZeneca Pharma India Ltd. (AZPIL) announced that the Central Drugs Standard Control Organisation (CDSCO) has approved an additional indication for trastuzumab deruxtecan 100 mg/5 mL vial lyophilised powder for concentrate for solution for infusion. The approval is for the adjuvant treatment of adult patients with HER2-positive (IHC 3+ or ISH+) breast cancer who have residual invasive disease following neoadjuvant trastuzumab (with or without pertuzumab) and taxane